ICON boosts leadership teams

Pharmaceutical service provider ICON has boosted its scientific operations, medical imaging and real world evidence leadership teams with three new senior appointments.

Dr Andrew Garrett (pictured right) joins ICON as executive vice president of scientific operations, with responsibility for the firm's global strategy and operational execution of its biostatistics and programming, pharmacovigilance, regulatory and medical affairs, medical writing, medical imaging and interactive technologies.

He has over 30 years of experience in pharmaceutical and contract research organisation (CRO) roles, joining from Quintiles where he led its global clinical analysis and reporting services group.

Dr Paul McCracken (pictured left) has been appointed as vice president of medical imaging, bringing over 20 years of expertise in applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas.

Most recently, Dr McCracken led the Imaging Centre of Excellence at Eisai, having previously worked at Merck Research Laboratories developing preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities.

Also joining ICON's leadership team, Jim Carroll (pictured below right) becomes vice president of real world evidence (RWE), leading the company's RWE Center of Excellence in the development of market access solutions.

Carroll has over 20 years of CRO and pharmaceutical experience, and joins ICON from inVentiv Health where he led its real world data (RWD)-driven service unit. Previously, Carroll oversaw IMS Health's RWD analytic solutions offering, helping to improve decision outcomes throughout a product's lifecycle.

Dr Steve Cutler, ICON's chief operating officer, said: “I'm delighted to welcome Andrew, Paul and Jim to the ICON team.

“The bring a wealth of scientific operational and commercialisation expertise to ICON which will help us to advance our clients' products through their development pipelines and also drive their commercial success.”